Daniel V Araujo, MD

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with…

Investigator

Daniel V Araujo

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as…

Investigator

Daniel V Araujo

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All